Jasper Therapeutics declared a 1-for-30 reverse stock split effective November 6, 2026, consolidating every 30 shares into one to increase its stock price and maintain Nasdaq listing compliance. The split will reduce outstanding shares from about 33.3 million to approximately 1.11 million, with proportional adjustments to warrants, options, and equity plans. Stockholders will not need to take action, and fractional shares will be cashed out. This move aims to support the company's market position as it advances its biotech pipeline.
Jasper Therapeutics' recent announcement of a 1-for-30 reverse stock split provides context for market watchers. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 121 rose and 23 fell. Notable movers include BRKR at USD 60.45 with a 1-day change of +6.99%, AMGN at USD 489.98 with a 1-day change of +6.23% and a Pluang order activity of 32% Sell / 68% Buy, and CRL at USD 330.01 with a 1-day change of -6.21%.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
